Unlearn.AI

Did you know that AI-generated #digitaltwins of trial participants can reduce control arm sizes by up to 33% or boost power by up to 10% in Phase 2 and 3 #ALS trials? Connect with us at #alsmndsymp on Dec. 6 to learn more about the value digital twins can bring to your #clinicaltrials. ?? ——— Motor Neurone Disease (MND) Association; Luis Olmos, PhD, MBA; Anurag Kulkarni; Coco Kusiak

Heading to Montreal for the 35th International Symposium on ALS/MND? ?? Connect with us to learn how our AI-generated participants’ #digitaltwins can optimize #clinicaldevelopment, from reducing control arm sizes to boosting power in #ALS studies. Register now: https://lnkd.in/eeeM2eRU ——— Motor Neurone Disease (MND) Association; Luis Olmos, PhD, MBA; Anurag Kulkarni; Coco Kusiak

Curious how the Unlearn Platform, which offers a suite of AI-powered solutions, can help streamline your clinical study? Visit https://bit.ly/3CxxgKS for details and to request a demo. ??

#UnlearnerSpotlight ?? Hanalei Pham Role: “I am responsible for building our Digital Twin Generators, from transforming clinical data into comprehensive data products to training and evaluating our models.” Favorite part about working at Unlearn: “My favorite part about working at Unlearn is the collaborative culture and the incredibly talented people I get to work with every day. Everyone is not only supportive but also driven to take on challenging problems. We’re encouraged to think creatively and tackle ambitious goals. It’s inspiring to be part of a team that’s not afraid to aim high and genuinely believes in making a difference.”

"Personally, I don't find it that interesting to think about how I can build an AI system that ?????????????????? ?????????? ???????????? ?????? ?????????????? ???? I want to focus on how I can create AI systems that invent new types of things, that extrapolate beyond human knowledge I want to create things that solve problems humans ???????????? ?????? ??????????.” ?? In the latest episode of the Talking Precision Medicine podcast, we had the pleasure of hosting Charles Fisher, founder and CSO of Unlearn.AI Find the full episode here:????https://lnkd.in/dXevEDSB Joined by Genialis' CEO, Rafael Rosengarten, they explore: ??How digital twins of patients could lead to faster and more cost-effective clinical trials ??The balance between the size and quality of datasets that train predictive models ??Why Charles doesn't say he's an entrepreneur when he introduces himself at parties

Unlearn Team at #CNSSummit2024! ?? It’s been an inspiring few days connecting with industry leaders dedicated to innovating healthcare. If we missed you, connect with us to learn how we’re partnering with biotech and pharma companies to streamline #clinicaltrials with #AI: https://bit.ly/473ZSa1 ——— CNS Summit; Anurag Kulkarni; Steven Herne; Luis Olmos, PhD, MBA

We are seeing something bigger emerge from the generative AI hype — a new stack and a new design paradigm. We call this “intelligence-first design,” a shift that positions AI within applications as a true collaborator, capable of amplifying human reasoning. The real transformation won’t come from layering incremental product updates; it will come from fundamentally redesigning applications and systems with intelligence and AI as a first-class citizen. Managing Director Ganesh Bell, VP Sophie Beshar, Director Ash Tutika, and Michael Spiro explore intelligence-first applications: ?? Emerging design patterns ?? Key archetypes ?? Some of the startups and ScaleUps in this new, emerging wave See how intelligence-first design and the Next Stack will unlock human+AI collaborative reasoning: https://lnkd.in/eEuc7nYi

Our Founder and VP of Technology, Jonathan Walsh, will be presenting at the Alzheimer's Association?’s Alzheimer’s Disease Neuroimaging Initiative Private Partner Scientific Board (ADNI-PPSB) on the topic of “Digital Twins in Drug Development.” His presentation will showcase diverse examples of #digitaltwin applications, focusing on regulatory qualifications and the integration of digital twins in #clinicaltrials. ?? Learn more: https://bit.ly/40BUkCc

?? Next week, our Senior Director of Clinical Affairs, Luis Olmos, PhD, MBA, will be joining Alexion Pharmaceuticals, Inc.’s “Stripes of Strength: Uniting for Rare Diseases” event—a gathering of leaders from various sectors focused on encouraging dialogue, sharing insights, and exploring collaboration opportunities in support of rare disease initiatives. Learn more: https://bit.ly/3YTPJdk

CNS Summit 2024 is just days away, and this year’s theme, “Driving the Future of Life Sciences,” closely aligns with our mission at Unlearn. As the only company advancing #AI models sophisticated enough to create #digitaltwins of individual study participants, we enable biotech and pharma companies to accelerate trials, improve reliability, and meet today’s rigorous standards in #clinicaldevelopment through our powerful tool—the Unlearn Platform. Discover how we’re reshaping the future of #clinicaltrials in CEO Steven Herne’s latest blog post. ??